Clinical Trials Logo

Keratoconjunctivitis clinical trials

View clinical trials related to Keratoconjunctivitis.

Filter by:

NCT ID: NCT03436576 Enrolling by invitation - Dry Eye Clinical Trials

Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye

Start date: September 12, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effects of autologous serum 20% and autologous serum 50% for the treatment of Severe Dry Eye Syndrome

NCT ID: NCT03418259 Completed - Clinical trials for Keratoconjunctivitis Sicca (KCS)

Intra-Nasal Mechanical Stimulation (INMEST) as a Treatment of Keratoconjunctivitis Sicca (Dry Eye Syndrome)

Start date: February 12, 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate how treatment with Intra-Nasal Mechanical Stimulation (INMEST) in the nasal cavity in patients with Keratoconjunctivitis sicca can relieve these symtoms.

NCT ID: NCT03408015 Withdrawn - Dry Eye Clinical Trials

Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease

Start date: January 2019
Phase: Phase 4
Study type: Interventional

Every night during sleep, there is an accumulation of white blood cells in the closed eye. The closed eye white blood cells are predominantly neutrophils, but there is a small population (3%) of T cells. The effects of these closed eye white blood cells on dry eye disease pathogenesis have yet to be fully elucidated, but preliminary evidence suggests that closed eye neutrophils may have an associated hyperactivity and increased degranulation in dry eye disease that could contribute to epithelial instability. As an anti-T cell therapy, Xiidra offers an opportunity to better understand how the closed eye white blood cells are recruited and activated. This study also seeks to verify the proposed mechanism of action.

NCT ID: NCT03398018 Withdrawn - Clinical trials for Keratoconjunctivitis Sicca

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Start date: November 1, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this pilot study is to assess repository corticotropin injection (RCI) in the form of H.P. Acthar Gel in patients with severe keratoconjunctivitis sicca (KCS, or dry eye disease). This pilot study is a non-randomized, open-label, interventional study to assess the efficacy and timeline of RCI for the treatment of severe KCS recalcitrant to conventional therapy. The purpose is to acquire preliminary data to support and guide the design of a future, double-masked, randomized, controlled clinical trial.

NCT ID: NCT03379311 Completed - Clinical trials for Vernal Keratoconjunctivitis

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

KRONOS
Start date: February 26, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.

NCT ID: NCT02970799 Completed - Dry Eye Clinical Trials

Tear Production by Nasal Neurostimulation Compared to Active Control

Start date: August 31, 2016
Phase: N/A
Study type: Interventional

This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones Schirmer test in participants with dry eye disease.

NCT ID: NCT02845674 Completed - Clinical trials for Keratoconjunctivitis Sicca

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Start date: July 29, 2016
Phase: Phase 3
Study type: Interventional

This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)

NCT ID: NCT02819284 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

STRIDE 2
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

NCT ID: NCT02813265 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

STRIDE 1
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

NCT ID: NCT02798289 Completed - Dry Eye Syndrome Clinical Trials

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

Start date: June 2016
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in participants with dry eye.